Appendix Table F122. Clinical outcomes after supervised PFMT combined with bladder training compared to self administered PFMT (results from RCTs pooled with random effects models)

Outcome	Reference	Active n/N	Control n/N	Rate active/control	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Continence	Bo, 2005[495]	13/21	4/26	60/17	4.02 (1.54; 10.53)	17.48	0.465 (0.215; 0.715)	18.61
Continence	de Oliveira Camargo, 2009[510]	14/30	16/30	47/53	0.88 (0.53; 1.46)	22.04	-0.067 (-0.319; 0.186)	24.66
Continence	Zanetti, 2007[623]	11/23	2/21	48/10	5.02 (1.26; 20.07)	11.75	0.383 (0.143; 0.623)	19.09
Continence	Burgio, 2002[505]	15/74	11/75	20/15	1.38 (0.68; 2.81)	25.95	0.056 (-0.066; 0.178)	18.48
Continence	Felicissimo, 2010[526]	11/31	11/31	37/35	1 (0.5; 1.9)	22.77	0 (-0.24; 0.24)	19.16
Pooled		64/179	44/183	36/24	1.6 (0.88; 2.9)	100	0.16 (-0.03; 0.35)	100
Heterogeneity P value, I squared,%					0.018	66.4%	0.003	75.1%
Improved UI	Zanetti, 2007[623]	15/23	5/21	67/24	2.74 (1.21; 6.23)	28.6	0.414 (0.147; 0.681)	24.5
Improved UI	Burgio, 2002[505]	36/74	20/75	49/27	1.82 (1.17; 2.84)	17.1	0.22 (0.068; 0.371)	16.59
Improved UI	Konstantinidou, 2007[551]	1/15	1/15	7/7	1 (0.07; 14.55)	2.65	0 (-0.179; 0.179)	22.52
Improved UI	de Oliveira Camargo, 2009[510]	18/30	20/30	60/67	0.9 (0.61; 1.33)	30.59	-0.067 (-0.31; 0.177)	18.03
Improved UI	Felicissimo, 2010[526]	11/31	11/31	37/35	1(0.51; 1.96)	21.06	0 (-0.24; 0.24)	18.36
Pooled		82/173	57/172	47/33	1.37 (0.87; 2.2)	100	0.11 (-0.05; 0.27)	100
Heterogeneity P value, I squared,%					0.05	57.9%	0.023	64.6%
Treatment failure	Konstantinidou, 2007[551]	4/15	7/15	27/47	0.86 (0.32; 2.30)	39.55	-0.056 (-0.405; 0.294)	26.35
Treatment failure	Bo, 2005[495]	1/21	7/26	5/27	0.18 (0.02; 1.33)	16.43	-0.222 (-0.415; -0.028)	44.5
Treatment failure	Aukee, 2004[486]	9/19	5/16	47/31	1.52 (0.64; 3.61)	44.03	0.161 (-0.158; 0.481)	29.15
Pooled		14/55	19/57	25/33	0.85 (0.34; 2.16)	100	-0.066 (-0.3; 0.167)	100
Heterogeneity P value, I squared,%					0.15	47.60%	0.126	51.70%
Treatment discontinuation	Tsai, 2009[611]	4/54	5/54	7/9	0.8 (0.23; 2.82)	49.05	-0.019 (-0.123; 0.086)	90.15
Treatment discontinuation	Konstantinidou, 2007[551]	3/15	5/15	20/33	0.79 (0.23; 2.7)	50.95	-0.063 (-0.379; 0.252)	9.85
Pooled		7/69	10/69	10/14	0.79 (0.33; 1.91)	100	-0.023 (-0.122; 0.076)	100
Heterogeneity P value, I squared,%					0.98	0.00%	0.791	0.00%